These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15595627)

  • 1. Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
    Popov IP; Jelic SB; Matijasevic MM; Grbic B; Babic DR
    J Exp Clin Cancer Res; 2004 Sep; 23(3):395-401. PubMed ID: 15595627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
    Moehler M; Hoffmann T; Hildner K; Siebler J; Galle PR; Heike M
    Z Gastroenterol; 2002 Dec; 40(12):957-64. PubMed ID: 12564419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
    Graeven U; Ridwelski K; Artandi M; Espana P; Schölmerich J; Rosales AM; Carlsson G; Borner M; Boussard B; Schmiegel W
    Oncol Rep; 2005 Apr; 13(4):681-8. PubMed ID: 15756442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
    Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
    Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
    J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
    Scartozzi M; Sobrero A; Gasparini G; Berardi R; Catalano V; Graziano F; Barni S; Zaniboni A; Beretta GD; Labianca R; Cascinu S;
    Oncology; 2005; 68(2-3):212-6. PubMed ID: 16015036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving role of oxaliplatin in the management of colorectal cancer.
    de Gramont A; Schmoll HJ; Cervantes A; Tournigand C
    Colorectal Dis; 2003 Nov; 5 Suppl 3():10-9. PubMed ID: 23573556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.
    Chang DZ; Abbruzzese JL
    Clin Adv Hematol Oncol; 2005 May; 3(5):400-4. PubMed ID: 16167013
    [No Abstract]   [Full Text] [Related]  

  • 10. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
    Carnaghi C; Zucali P; Garassino I
    Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for colorectal cancer.
    Goyle S; Maraveyas A
    Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
    Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC
    Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.
    Vamvakas L; Kakolyris S; Kouroussis C; Kandilis K; Mavroudis D; Ziras N; Androulakis N; Kalbakis K; Sarra E; Souglakos J; Georgoulias V;
    Am J Clin Oncol; 2002 Feb; 25(1):65-70. PubMed ID: 11823700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy.
    Recchia F; Rea S; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Massa E; Mantovani G
    Oncol Rep; 2003; 10(1):65-9. PubMed ID: 12469146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the role of CPT-11 in the treatment of colorectal cancer.
    Rougier P; Mitry E
    Clin Colorectal Cancer; 2001 Aug; 1(2):87-94. PubMed ID: 12445366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
    Ferrari V; Valcamonico F; Amoroso V; Simoncini E; Vassalli L; Marpicati P; Rangoni G; Grisanti S; Pasinetti N; Marini G
    Oncology; 2005; 69(4):283-9. PubMed ID: 16282707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
    Rothenberg ML; Oza AM; Bigelow RH; Berlin JD; Marshall JL; Ramanathan RK; Hart LL; Gupta S; Garay CA; Burger BG; Le Bail N; Haller DG
    J Clin Oncol; 2003 Jun; 21(11):2059-69. PubMed ID: 12775730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.